Stockscreener 앱 받기
12.92
1.15%
-0.15
시간 외 거래:
13.39
0.47
+3.64%
Corvus Pharmaceuticals Inc 주식(CRVS)의 최신 뉴스
BlackRock (CRVS holder) reports 7.5% beneficial stake in Corvus Pharmaceuticals - Stock Titan
Corvus Pharmaceuticals Inc (CRVS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
CRVS|Corvus Pharmaceuticals Inc|Price:13.610|Chg%:+0.540 - TradingKey
Corvus Pharmaceuticals Inc (CRVS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
CRVS|Corvus Pharmaceuticals Inc|Price:12.925|Chg%:-0.145 - TradingKey
CRVS Stock Surges 10%, Hits 50-DMA For First Time In A Month – Here’s Why Goldman Sachs Sees A 166% Upside - Stocktwits
Corvus Pharmaceuticals Inc (CRVS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Corvus Pharmaceuticals Inc (CRVS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Corvus Pharmaceuticals Inc (CRVS) Valuation: PE, PB & Fair Value Analysis - TradingKey
Corvus Pharmaceuticals Inc (CRVS) Institutional Confidence - TradingKey
CRVS|Corvus Pharmaceuticals Inc|Price:13.070|Chg%:-0.610 - TradingKey
TradingKey - TradingKey
Corvus Pharmaceuticals, Inc. Revenue Breakdown – BX:C17 - TradingView
Corvus Pharmaceuticals director Ian T. Clark resigns from board - Bitget
Corvus Pharmaceuticals Announces Board Leadership Transition - TipRanks
Corvus Pharmaceuticals (CRVS) Slips 2.9% as Stock Tests Support Near $13.35Negative Gamma - dars.gov.et
Corvus Pharmaceuticals (CRVS) Q1 2026 earnings summary - Quartr
Corvus Pharmaceuticals (CRVS) Proxy filing Summary - Quartr
CRVS News | CORVUS PHARMACEUTICALS INC (NASDAQ:CRVS) - ChartMill
Corvus Pharmaceuticals (CRVS) Q1 2025 earnings summary - Quartr
Corvus Pharmaceuticals (CRVS) Rallies 2.11% to $15.49, Approaching Resistance at $16.26Option Strike Build - dars.gov.et
Corvus Pharmaceuticals (CRVS) Stock Analysis Report | Financials & Insights - Benzinga España
Corvus Pharmaceuticals (CRVS) Gains 1.42% as Biotech Momentum Lifts Speculative NamesDaily Profile - dars.gov.et
Corvus Pharmaceuticals (CRVS) Gains 3.18% as Biotech Sector Finds Its FootingNew Listing Stocks - dars.gov.et
Is Corvus Pharmaceuticals (CRVS) Still Undervalued After Its Share Price Jump? - Sahm
Corvus Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:CRVS) - TradingView
Corvus Pharmaceuticals, Inc. Actuals & Estimates (BX:C17) - TradingView
Corvus Pharmaceuticals, Inc. Actuals & Estimates (SWB:C17) - TradingView
Corvus Pharmaceuticals, Inc. Actuals & Estimates (DUS:C17) - TradingView
CRVS Forecast — Price Target — Prediction for 2027 - TradingView
Corvus Pharmaceuticals (CRVS) Short Interest & Short Float | Updated Jun 2026 - MarketBeat
Price to book forward of Corvus Pharmaceuticals, Inc. – NASDAQ:CRVS - TradingView
Price to sales forward of Corvus Pharmaceuticals, Inc. – NASDAQ:CRVS - TradingView
Corvus Pharmaceuticals Director Buys 21,700 Shares. Does This Mean CRVS a Buy? - Yahoo Finance
Corvus Pharmaceuticals Director Buys 21,700 Shares. Does This Mean CRVS a Buy? - The Motley Fool
Corvus Pharmaceuticals Inc (CRVS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Insider Buys Additional US$250k In Corvus Pharmaceuticals Stock - simplywall.st
Corvus Pharmaceuticals Inc (CRVS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Corvus Pharmaceuticals Inc (CRVS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Corvus CEO thinks his next blockbuster is an ITK inhibitor - Pharma Voice
Corvus Pharmaceuticals (CRVS) director buys 21,700 shares and receives 15,000-share option - Stock Titan
[Form 4] Corvus Pharmaceuticals, Inc. Insider Trading Activity - Stock Titan
Corvus Pharmaceuticals (CRVS) director receives grant of 15,000 stock options - Stock Titan
Director at Corvus (CRVS) receives grant of 15,000 stock options - Stock Titan
Corvus (CRVS) director awarded options for 15,000 shares at $11.60 - Stock Titan
Corvus Pharmaceuticals Faces Key Soquelitinib Data And Possible M&A Interest - Yahoo Finance
Is Corvus Pharmaceuticals, Inc. (CRVS) A Good Stock To Buy Now? - Insider Monkey
Corvus Stockholders Approve Directors and Governance Proposals - TipRanks
1.97%
0.83%
자본화:
|
볼륨(24시간):